Clinical Trial Update: A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update showing recruitment for a study comparing Romiplostim N01 versus recombinant human interleukin-11 for cancer therapy-induced throm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Therapy-induced Thrombocytopenia

Drugs mentioned

• Recombinant Human Interleukin-11 (interleukin-11)
• Romiplostim N01 (romiplostim)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: CTIT: Cancer Therapy Induced Thrombocytopenia | Phase 3 | Status: RECRUITING